FDA Mission Should Not Include Rx Cost Effectiveness, Rep. Allen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Comparative studies should be "untainted" by industry's influence, the Maine Democrat says. He urges full appropriation of funding to AHRQ under the new Medicare law.
You may also be interested in...
CMS Plans To Issue Clinical Evidence Position Paper In August
The coverage process could provide an incentive for well-designed practical clinical trials, CMS Chief Medical Officer Tunis says during a Drug & Device Dialogue audio conference. The paper will describe the agency’s activities in designing clinical studies.
CMS Plans To Issue Clinical Evidence Position Paper In August
The coverage process could provide an incentive for well-designed practical clinical trials, CMS Chief Medical Officer Tunis says during a Drug & Device Dialogue audio conference. The paper will describe the agency’s activities in designing clinical studies.
CMS, Industry To Debate "Practical Clinical Trials" During July 20 Audio Conference
CMS Chief Medical Officer Tunis and former FDA device center director Feigal, along with J&J and Medtronic reps, will debate the benefits and pitfalls of practical clinical research during a Drug & Device Dialogue hosted by FDC Reports in partnership with Polidais LLC.